GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma
Provider: View Press Release Type: Link Title: GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed/refractory multiple myeloma | GSK Description: Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex.
GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials
Provider: View Press Release Type: Link Title: GSK announces major step towards sustainability ambitions with advancement of low carbon Ventolin programme to Phase III trials | GSK Description: Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler.
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
Provider: View Press Release Type: Link Title: GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia | GSK Description: Decision on EU marketing authorisation expected for momelotinib by early 2024.
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen
Provider: View Press Release Type: Link Title: GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen | GSK Description: GSK plc and Arrowhead Pharmaceuticals Inc. today announced that they have reached an agreement with Janssen Pharmaceuticals, Inc.
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer
Provider: View Press Release Type: Link Title: Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer | GSK Description: Statistically significant and clinically meaningful overall survival benefit observed in the overall population in the trial.
